Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer.

Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer.

Glycogen synthase kinase-3 (GSK3) is over-expressed and hyperactivated in non-small cell lung carcinoma (NSCLC) and plays a role in ensuring the correct alignment of chromosomes on the metaphase plate during mitosis through regulation of microtubule stability. This makes the enzyme an attractive tar...

Full description

Bibliographic Details
Main Authors: Linda O'Flaherty, Steven D Shnyder, Patricia A Cooper, Stephen J Cross, James G Wakefield, Olivier E Pardo, Michael J Seckl, Jeremy M Tavaré
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0214610

Internet

https://doi.org/10.1371/journal.pone.0214610

Similar Items